Yannis Morel

6.0k total citations · 1 hit paper
52 papers, 2.6k citations indexed

About

Yannis Morel is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Yannis Morel has authored 52 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Immunology, 15 papers in Molecular Biology and 15 papers in Oncology. Recurrent topics in Yannis Morel's work include Immune Cell Function and Interaction (22 papers), Immunotherapy and Immune Responses (11 papers) and Immune Response and Inflammation (9 papers). Yannis Morel is often cited by papers focused on Immune Cell Function and Interaction (22 papers), Immunotherapy and Immune Responses (11 papers) and Immune Response and Inflammation (9 papers). Yannis Morel collaborates with scholars based in France, United States and Switzerland. Yannis Morel's co-authors include Éric Vivier, Olivier Demaria, Stéphanie Cornen, Marc Daëron, Ruslan Medzhitov, Carine Paturel, Sandra S. Diebold, Shizuo Akira, Catherine Massacrier and Daniel Olive and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Yannis Morel

50 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Harnessing innate immunity in cancer therapy

2019 702 citations Olivier Demaria, Stéphanie Cornen et al. Nature profile →

Peers

Countries citing papers authored by Yannis Morel

Since Specialization

Citations

This map shows the geographic impact of Yannis Morel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yannis Morel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yannis Morel more than expected).

Fields of papers citing papers by Yannis Morel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yannis Morel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yannis Morel. The network helps show where Yannis Morel may publish in the future.

Co-authorship network of co-authors of Yannis Morel

This figure shows the co-authorship network connecting the top 25 collaborators of Yannis Morel. A scholar is included among the top collaborators of Yannis Morel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yannis Morel. Yannis Morel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123 2023 ·Nature Biotechnology ·Laurent Gauthier, Angéla Virone-Oddos, Jochen Beninga, Benjamín Rossi, Céline Nicolazzi, Céline Amara, (unknown), Nicolas Gourdin, (unknown), (unknown), (unknown), (unknown), Gwendoline Grondin, (unknown), Anne-Laure Bauchet, Ariane Morel, Yannis Morel, Marielle Chiron, Éric Vivier	62
2	852 Trifunctional NKp46/CD16a-NK cell engager targeting CD123 overcomes acute myeloid leukemia resistance to ADCC 2021 ·SHILAP Revista de lepidopterología ·Laurent Gauthier, Angéla Virone-Oddos, Jochen Beninga, Benjamín Rossi, Céline Nicolazzi, Céline Amara, (unknown), Nicolas Gourdin, (unknown), (unknown), (unknown), Gwendoline Grondin, (unknown), Anne-Laure Bauchet, Ariane Morel, Yannis Morel, Marielle Chiron, Éric Vivier	2
3	Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19 2020 ·Cellular and Molecular Immunology ·Olivier Demaria, Julien Carvelli, Luciana Batista, Marie‐Laure Thibult, Ariane Morel, Pascale André, Yannis Morel, Frédéric Vely, Éric Vivier	57
4	Harnessing innate immunity in cancer therapy breakdown → 2019 ·Nature ·Olivier Demaria, Stéphanie Cornen, Marc Daëron, Yannis Morel, Ruslan Medzhitov, Éric Vivier	702
5	Abstract 5037: Targeting MICA with therapeutic antibodies for the treatment of cancer 2014 ·Cancer Research ·Mathieu Bléry, Cécile Bonnafous, Valentine Péri, Sylvia Trichard, Ivan Perrot, Stéphanie Cornen, Ariane Thielens, (unknown), Yannis Morel, François Romagné, Benjamín Rossi, Carine Paturel, Laurent Gauthier	1
6	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide 2014 ·Haematologica ·(unknown), Jeroen J. Lammerts van Bueren, Berris van Kessel, Pascale André, Yannis Morel, H M Lokhorst, Niels W.C.J. van de Donk, Paul W.H.I. Parren, Tuna Mutis	89
7	The Toll-Like Receptor Agonist Imiquimod Is Active against Prions 2013 ·PLoS ONE ·Nassima Oumata, (unknown), Vincent Béringue, (unknown), (unknown), Nathalie Desban, Catherine Massacrier, Yannis Morel, Carine Paturel, (unknown), Serge Bouaziz, Suparna Sanyal, Hervé Galons, Marc Blondel, Cécile Voisset	24
8	TLR3 as a Biomarker for the Therapeutic Efficacy of Double-stranded RNA in Breast Cancer 2011 ·Cancer Research ·Bruno Salaun, Laurence Zitvogel, Carine Asselin‐Paturel, Yannis Morel, Karine Chemin, (unknown), Catherine Massacrier, Rosa Conforti, Marie Pierre Chenard, Jean‐Christophe Sabourin, Aïcha Goubar, Serge Lebecque, Michel Pierres, Donata Rimoldi, Pedro Romero, Fabrice André	93
9	Opposing Effects of Toll-like Receptor (TLR3) Signaling in Tumors Can Be Therapeutically Uncoupled to Optimize the Anticancer Efficacy of TLR3 Ligands 2010 ·Cancer Research ·Rosa Conforti, Yuting Ma, Yannis Morel, Carine Paturel, Magali Terme, Sophie Viaud, Bernard Ryffel, Maria Ferrantini, Ravindra Uppaluri, Robert D. Schreiber, Christophe Combadière, Nathalie Chaput, Fabrice André, Guido Kroemer, Laurence Zitvogel	87
10	Desirable cell death during anticancer chemotherapy 2010 ·Annals of the New York Academy of Sciences ·Clara Locher, Rosa Conforti, Laetitia Aymeric, Yuting Ma, Takahiro Yamazaki, Sylvie Rusakiewicz, Antoine Tesnière, François Ghiringhelli, Lionel Apétoh, Yannis Morel, Jean‐Philippe Girard, Guido Kroemer, Laurence Zitvogel	62
11	Plasmacytoid dendritic cell–derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists 2010 ·Blood ·Deepa Rajagopal, Carine Paturel, Yannis Morel, Satoshi Uematsu, Shizuo Akira, Sandra S. Diebold	96
12	17beta-hydroxysteroid dehydrogenase deficiency caused by homozygous h271r mutation 2006 ·Anne Bachelot, Zeina Chakhtoura, F Kuttenn, Yannis Morel, P. Touraine	3
13	Nucleic acid agonists for Toll‐like receptor 7 are defined by the presence of uridine ribonucleotides 2006 ·European Journal of Immunology ·Sandra S. Diebold, Catherine Massacrier, Shizuo Akira, Carine Paturel, Yannis Morel, Caetano Reis e Sousa	219
14	Phosphostim-Activated γδ T Cells Kill Autologous Metastatic Renal Cell Carcinoma 2005 ·The Journal of Immunology ·(unknown), Gaëlle Fromont, Bernard Escudier, Yannis Morel, Sylvie Da Rocha, Salem Chouaı̈b, Anne Caignard	164
15	Mechanisms Regulating Expression of the Tumor Necrosis Factor-related light Gene 2002 ·Journal of Biological Chemistry ·Rémy Castellano, Carine Van Lint, Valentine Péri, (unknown), Yannis Morel, Régis Costello, Daniel Olive, Yves Collette	19
16	The TNF Superfamily Members LIGHT and CD154 (CD40 Ligand) Costimulate Induction of Dendritic Cell Maturation and Elicit Specific CTL Activity 2001 ·The Journal of Immunology ·Yannis Morel, Alemseged Truneh, Raymond W. Sweet, Daniel Olive, Régis Costello	143
17	Reciprocal Expression of the TNF Family Receptor Herpes Virus Entry Mediator and Its Ligand LIGHT on Activated T Cells: LIGHT Down-Regulates Its Own Receptor 2000 ·The Journal of Immunology ·Yannis Morel, Jean‐Marc Schiano de Colella, (unknown), Keith C. Deen, Stephen D. Holmes, Trevor Wattam, Sanjay S. Khandekar, Alemseged Truneh, Raymond W. Sweet, Jean‐Albert Gastaut, Daniel Olive, Régis Costello	143
18	Personalities and alimentary behaviors in obese patients 1997 ·Patient Education and Counseling ·Alain Golay, (unknown), (unknown), Patrick Rouget, Anne‐Françoise Allaz, Yannis Morel, J Nicolet, Marc Archinard	11
19	Insulin Sensitivity in Obese Hypertensive Dyslipidemic Patients Treated with Enalapril or Atenolol 1995 ·Journal of Cardiovascular Pharmacology ·Yannis Morel, (unknown), U Keller, L. Vadas, Alain Golay	33
20	Inhibition of the MtTF4 tumor growth by dexamethasone 1988 ·Journal of Steroid Biochemistry ·(unknown), (unknown), Yannis Morel, J. Trouillas, Jean André	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact